Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints

Loading news article.

Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints | WAPE

Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints

Article summary

Related companies

Comments —